Stichting Dutch
Uro-Oncology
Studygroup (DUOS)

Lutetium en Actinium PSMA in Nederland

5 december, 2021 - De komende maanden en vooral voorjaar 2022 zal In Nederland behandeling met LutetiumPSMA langzaam op gang komen. Enkele ziekenhuizen hebben toestemming gekregen deze behandeling uit te gaan voeren. In...

Zorgen of angst bij kanker, wat is uw er...

5 december, 2021 - Een nieuwe ‘Doneer Je Ervaring’-peiling met de hoofdvraag “Zorgen of angst bij kanker, wat is uw ervaring?”. Met deze peiling wil NFK achterhalen of mensen die kanker hebben of...

Nieuwe EAU richtlijn Renal Cell Carcinoma

4 december, 2021 - Updated guidelines on the management of renal cell carcinoma (RCC) were published in October 2021 by the European Association of Urology (EAU) in European Urology. If the results of contrast-enhanced...

Nivolumab-Cabozantinib combinatie boosts...

4 december, 2021 - Previously untreated patients with advanced renal-cell carcinoma live twice as long without disease progression when given a combination of nivolumab and cabozantinib instead of sunitinib, according to results from...

Lenvatinib-Pembrolizumab combinatie veel...

4 december, 2021 - The combination of the multikinase inhibitor lenvatinib and the anti-PD-1 antibody pembrolizumab has “encouraging” antitumor activity and a manageable side effect profile and might be an option following immune-checkpoint...

FDA keurt adjuvant pembrolizumab goed bi...

4 december, 2021 - Pembrolizumab (Keytruda) has been granted approval from the US Food and Drug Administration for use as an adjuvant treatment following surgery in certain patients with renal cell carcinoma (RCC), making...